RADX
Income statement / Annual
Last year (2023), Radiopharm Theranostics Limited's total revenue was $299.23 K,
an increase of 2.35% from the previous year.
In 2023, Radiopharm Theranostics Limited's net income was -$47.95 M.
See Radiopharm Theranostics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
| Operating Revenue |
$299.23 K |
$292.36 K |
$8.83 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$299.23 K
|
$292.36 K
|
$8.83 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
| Research and Development Expenses |
$17.56 M
|
$13.80 M
|
$4.12 M
|
| General & Administrative Expenses |
$15.22 M
|
$13.02 M
|
$10.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.22 M
|
$13.02 M
|
$10.85 M
|
| Other Expenses |
$4.14 M
|
$7.98 M
|
$4.95 M
|
| Operating Expenses |
$36.92 M
|
$34.80 M
|
$19.93 M
|
| Cost And Expenses |
$36.92 M
|
$34.80 M
|
$19.93 M
|
| Interest Income |
$50.48 K
|
$145.04 K
|
$0.00
|
| Interest Expense |
$642.89 K
|
$86.09 K
|
$9.35 M
|
| Depreciation & Amortization |
$3.13 M
|
$3.30 M
|
$2.98 M
|
| EBITDA |
-$44.08 M |
-$31.19 M |
-$17.96 M |
| EBITDA Ratio |
-147.32
|
-106.69
|
-2034.13
|
| Operating Income Ratio |
-122.38
|
-118.03
|
-2255.28
|
| Total Other Income/Expenses Net |
-$11.23 M
|
-$65.10 K
|
-$10.38 M
|
| Income Before Tax |
-$47.85 M
|
-$34.57 M
|
-$30.29 M
|
| Income Before Tax Ratio |
-159.92
|
-118.26
|
-3430.48
|
| Income Tax Expense |
$96.36 K
|
$38.01 K
|
$44.40 K
|
| Net Income |
-$47.95 M
|
-$34.61 M
|
-$30.34 M
|
| Net Income Ratio |
-160.24
|
-118.39
|
-3435.51
|
| EPS |
0 |
0 |
-29.76 |
| EPS Diluted |
0 |
0 |
-29.76 |
| Weighted Average Shares Out |
$1.29 M
|
$1.02 M
|
$1.02 M
|
| Weighted Average Shares Out Diluted |
$1.29 M
|
$1.02 M
|
$1.02 M
|
| Link |
|
|
|
